Recent discussions have highlighted a surprising consequence of the Trump administration’s tariffs, which have primarily focused on items like cars and phones. They are beginning to influence prices in the healthcare sector.
On Monday, Matt McGau from the nonprofit organization KFF shared insights on the matter. Some insurance companies are already alerting state regulators about impending premium increases aimed at compensating for the expected effects of these tariffs on medication costs.
Although the Trump administration hasn’t specifically targeted drug prices with tariffs, the subject has been frequently mentioned by him, including during a recent flight on Air Force One. “We’re going to tackle medicines very soon,” he stated. “This will bring businesses back to America.”
In May, the Independent Health Beneficiary Corporation (IHBC) announced a significant rate increase of 38.4% for premiums in 2026. A representative from IHBC informed Axios that approximately 3% of this hike could be attributed directly to the tariffs affecting drug prices.
There are other insurers who either have chosen not to reference tariffs directly or have opted not to include increased premium rates for the upcoming year.
According to McGough, most medical supplies, including medications and essential devices, are sourced internationally. “Tariffs levelled on these items might jeopardize access to critical medicines and necessary medical devices,” he cautioned. “Additionally, this could escalate hospital costs and lead to shortages and disruptions in the supply chain.”
At the same time, millions who rely on the Affordable Care Act (ACA) could see their premiums skyrocket by over 75% if Congress fails to extend Biden-era subsidies before they lapse at the year’s end.
More details regarding the effects of tariffs on insurance rates will become clearer on August 1, when the proposed premium rates for 2026 are expected to be revealed.
